Drug intelligence / Profile preview

PSB220

Development stage: Preclinical
Lead developer: Sound Biologics

Overview

PSB220 is an investigational therapeutic candidate being developed by Sound Biologics for the treatment of immunological and inflammatory disorders. As of early 2024, the specific biological targets and molecular modality of the drug remain undisclosed by the company. It is part of Sound Biologics' pipeline, which focuses on developing multispecific antibody therapies, although it is not yet confirmed if PSB220 utilizes their proprietary MabPair platform. The program is currently in the early stages of development, with specific clinical phases not yet publicly defined.

Beyond the preview

Go deeper on PSB220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB220.

Explore the full profile